证券日报网讯 2月25日，东阿阿胶在互动平台回答投资者提问时表示，截至2026年2月13日，公司股东 人数为69483户。 （文章来源：证券日报） ...

大健康产业是关乎民生福祉、承载经济转型希望的新兴产业,也是聊城市重点打造的4条标志性产业链之 一。2025年以来,全市以《聊城市大健康产业发展规划(2024—2028年)》为蓝图,聚焦医药制品、健康食 品、医疗器械三大领域,将品牌建设作为核心引擎,着力推动产业链从"单点突破"向"集群协同"升级,从"传 统制造"向"高端智造"跨越。 目前,全市大健康产业链规上企业达52家,2025年实现产值114.5亿元,同比增长9.8%；营业收入102.7亿元, 同比增长6.2%；利润总额20.3亿元,同比增长13.2%,呈现出稳健向上的发展态势。特别值得一提的是,东 阿阿胶（000423）、冠县灵芝产业集群先后入选省级医养健康特色产业集群；全市大健康产业集群入选 省"十强产业"雁阵形产业集群储备库；聊城市参与联合申报的沿黄中医药产业集群入选省"十强产业"支 柱型雁阵集群,品牌赋能的叠加效应持续释放。 聊城市卫生健康委员会举行"品牌赋能大健康产业高质量融合发展"主题发布会,聊城市计划生育协会副 会长、大健康产业链专班办公室主任纪浩晴介绍了聊城市大健康产业链发展的有关情况。 陶春燕 聊城报道 构建品牌矩阵 筑牢产业发展"金招牌 ...

正月初六上午，从天津自驾而来的许先生一家，在东阿阿胶主力生产厂区"阿胶世界"的探秘长廊里看得 入迷：巨大的不锈钢化皮机取代了传统熬胶的敞口大锅，机械臂在智能化产线上灵活翻飞，视觉检测系 统为每一块即将出厂的阿胶进行"全身体检"。然而，并非所有工序都被机器取代，关键的"擦胶"环节依 旧沿用古法，工人们用浸过纯化水的老粗布将暗淡的胶块擦拭至色如琥珀。 马年春节期间，《证券日报》记者探访了山东聊城东阿县。在这座以阿胶闻名的小城，当地支柱企业东 阿阿胶股份有限公司（以下简称"东阿阿胶"）依托深厚的中医药文化底蕴，将生产线、毛驴繁育基地和 古城景区等打包成独特的工业旅游线路，构建起贯通一、二、三产的工业旅游全产业链。 当不少人厌倦了网红城市和知名景区的拥挤，东阿阿胶提供了一种稀缺的假期体验：远离喧嚣人潮，尽 享被文化包裹的慢生活。工业旅游串起的不仅是景点，更是一种可沉浸、可体验、可带走的年味。 老字号里的"新"年味 参观生产厂区时，每到一个区域都能闻到不同的香气：阿胶枣生产区枣香沁脾，阿胶块生产区药香浓 郁，阿胶糕产区则夹杂着核桃、芝麻的干果香。"我们就是要通过'五觉'的沉浸式体验，让游客感受近 3000年阿胶文化的博 ...

Core Viewpoint - The acquisition and evolution of the direct selling license by Dong'e Ejiao reflect not only the strategic choices of a single enterprise but also the profound changes in the industry from institutional arbitrage to value return over the past decade [1]. Group 1: Institutional Foundation - The issuance of the direct selling management regulations in 2005 marked the beginning of the legal framework for the direct selling industry in China, distinguishing between legal direct selling and illegal pyramid schemes [3]. - Dong'e Ejiao's direct selling license approval in 2015 occurred during a critical transition period for the industry, characterized by a shift from chaotic growth to regulated operations [3]. - The rigorous qualification process for obtaining a direct selling license underscores its significance as a testament to a company's brand reputation, product quality, and management system [3]. Group 2: Strategic Choices - Dong'e Ejiao entered the direct selling sector due to its need to diversify sales channels, as it faced a decline in revenue from traditional distribution methods [6]. - The direct selling model aligns well with the characteristics of Dong'e Ejiao's products, which require in-depth explanation and have clear repurchase cycles, making it suitable for face-to-face health consultations [6]. - The direct selling approach allows Dong'e Ejiao to enhance profitability while providing consumers with more accessible pricing, thus creating a win-win situation [6]. Group 3: Endowment Support - Dong'e Ejiao's unique brand heritage and ongoing technological innovation are key factors that enable its success in the direct selling arena [7]. - The company has established significant assets, including a national engineering research center and participation in the formulation of national pharmacopoeia standards, which bolster its confidence in entering the direct selling market [7]. - Dong'e Ejiao's strategic shift towards technology-driven growth has led to increased R&D investment, reaching 210 million yuan in 2024, a 27.63% increase year-on-year [7]. Group 4: Industry Changes - Over the past decade, the direct selling industry in China has transitioned from a focus on license acquisition to a more rational return to the essence of the industry [11]. - The industry has seen a decline in growth rates, with 13 licensed companies suspending or abandoning their direct selling operations between 2023 and 2024 [11]. - The future of direct selling is expected to evolve into a model centered on technology empowerment and community interaction, emphasizing the importance of creating irreplaceable customer value [11]. Group 5: Rational Examination - Despite obtaining the direct selling license, Dong'e Ejiao has not rapidly expanded its direct selling business, reflecting a cautious approach influenced by various external factors [14]. - The company recognizes the dual-edged nature of the direct selling model and has chosen to prioritize brand reputation over immediate sales growth [14]. - The strategic value of the direct selling license lies in its potential to facilitate deeper consumer engagement and future business innovations, particularly in the context of increasing health awareness [15]. Conclusion - The ten-year journey of Dong'e Ejiao's direct selling license represents a significant period of maturation for the Chinese direct selling industry and highlights the balance between institutional benefits and corporate endowments [17]. - The direct selling license serves as a baseline for compliant operations, a testament to brand credibility, and a reflection of the industry's return to value [17].

Group 1 - On February 15, 2026, Shandong Province's key monitored tourist attractions received 1.666 million visitors and generated revenue of 92.82 million yuan [1] - Various cultural and folk activities were organized, including intangible cultural heritage experiences and traditional lantern festivals, enhancing the festive atmosphere [1] - The integration of traditional customs with modern celebrations has become a mainstream experience during the holiday [1] Group 2 - Multiple tourist attractions in Linyi and Jining launched themed events and activities, such as the "Cultural Jining" lantern festival, which combines traditional lantern art with modern technology [2] - The tourism market's consumption potential was effectively released through policies like ticket discounts and hotel promotions, stimulating market vitality [2] - The "Five Blessings" consumption season in Zaozhuang was strategically planned to enhance local tourism activities [2] Group 3 - Over 30 scenic spots in Yantai offered free or discounted entry, while hotels provided special winter packages and dining options to attract visitors [3] - The winter tourism sector, including ice and snow activities, has shown significant growth, with various events and experiences being organized across the province [5] - The integration of wellness and cultural experiences, such as hot spring and cultural tourism packages, has emerged as a new trend [5] Group 4 - Public cultural venues across the province saw increased attendance, with many offering free access and diverse activities, promoting cultural engagement during the holiday [6] - Various cultural events, including exhibitions and interactive experiences, were organized to enhance community participation and cultural appreciation [7] - The market for cultural and tourism integration is thriving, with innovative experiences and improved product offerings attracting visitors [8]

证券日报网讯2月13日，东阿阿胶（000423）在互动平台回答投资者提问时表示，截至2026年2月10日， 公司股东总数为71307户。 ...

Group 1 - Xinda Biopharmaceutical announced a strategic collaboration with Eli Lilly to advance global R&D of innovative drugs in oncology and immunology, with a total potential value of up to $88.5 billion [1] - Under the agreement, Xinda will receive an upfront payment of $350 million and may earn up to approximately $8.5 billion in milestone payments related to R&D, regulatory, and commercialization achievements [1] - Xinda retains all rights for the projects in Greater China, while Eli Lilly obtains exclusive development and commercialization rights outside this region [1] Group 2 - Kangtai Biological announced the termination of its collaboration with AstraZeneca to establish a joint venture in the vaccine sector, which was initially planned to be set up in Beijing with a registered capital of approximately 345 million yuan (about $50 million) [2] - The decision to terminate was made due to significant market changes and increased investment risks in the vaccine industry, with no adverse impact on Kangtai's operations [2] Group 3 - China Resources Pharmaceutical announced plans to sell approximately 17.87% of its stake in Tianmai Biotechnology for a base price of about 1.42 billion yuan [3] - The sale will be conducted through a public listing, and as of the announcement date, China Resources holds less than 30% of Tianmai's shares [3] Group 4 - Dong'e Ejiao plans to invest 1.485 billion yuan to construct a health consumer goods industrial park, with a construction period of approximately 22 months [4] - The project aims to support the high-quality development of the health consumer goods business, including the production of food and health products [4] Group 5 - WuXi Biologics expects a revenue increase of approximately 16.7% to 21.79 billion yuan for the fiscal year ending December 31, 2025, with a projected profit growth of 45.3% to 5.733 billion yuan [5] - The growth is attributed to successful execution of its "Follow and Win" strategy, expansion of service offerings, and increased utilization of production capacity [7] Group 6 - Kintor Pharmaceutical signed a strategic cooperation agreement to expand its CAR-T cell therapy production base in Shanghai, with a total investment of up to 370 million yuan [8] - This initiative aligns with the commercialization of multiple CAR-T products and aims to enhance production capacity to support global competitiveness [8]

Core Viewpoint - Dong-E E-Jiao is investing 1.485 billion yuan to build a health consumer goods industrial park, supporting its "1238" development strategy aimed at enhancing its dual business model of pharmaceuticals and health consumer products [1][2][3] Group 1: Investment and Strategic Development - The company plans to invest 1.485 billion yuan, with 1.421 billion yuan allocated for fixed assets and 0.64 billion yuan for working capital, to establish a health consumer goods industrial park [2] - The project will focus on the production of health consumer products, including food and health supplements, and will include facilities for quality inspection, e-commerce sorting, and storage [2][3] - The construction site is located in the Economic Development Zone of Dong'e County, Shandong Province, covering an area of 406,800 square meters, with a planned construction period of approximately 22 months [2][3] Group 2: Financial Performance and Shareholder Returns - Dong-E E-Jiao has shown consistent growth in revenue and net profit from 2020 to 2024, with revenue increasing from 3.409 billion yuan in 2020 to 5.921 billion yuan in 2024, and net profit rising from 0.43 billion yuan to 1.557 billion yuan during the same period [4][5] - The company has maintained a high dividend payout ratio, distributing a total of 4.081 billion yuan in dividends over five years, which exceeds its net profit during that period [6][7] - In the first three quarters of 2025, the company reported revenue of 4.766 billion yuan and a net profit of 1.274 billion yuan, reflecting a year-on-year growth of 4.41% and 10.53%, respectively [5][6]

Core Viewpoint - Dong'e Ejiao is making a significant investment of 1.485 billion yuan to build a health consumer goods industrial park, which is a strategic move to adapt to the trend of younger consumers and the foodification of products in the ejiao industry [2][3]. Investment Details - The total investment of 1.485 billion yuan includes 1.421 billion yuan for fixed assets and 64 million yuan for working capital, indicating a focus on capacity construction for health consumer goods [2][3]. - This investment is the largest single investment in the health consumer sector in recent years, highlighting the company's commitment to scaling production capabilities [3]. Market Trends - The consumer base for ejiao is expanding from "middle-aged women" to "universal health," with younger consumers driving demand for ready-to-eat products [3][5]. - By 2025, ready-to-eat ejiao products are expected to account for over 60% of the market, with 62% of young users preferring "ready-to-eat" formats [3]. Capacity and Financial Position - The construction of the industrial park aims to address the current capacity limitations in health consumer goods, which have been a barrier to rapid market growth for new products [4]. - As of Q3 2025, the company has total assets of 12.749 billion yuan and a low debt ratio of 21.77%, providing a solid financial foundation for the investment [4]. Industry Context - The ejiao industry has undergone significant changes, moving from price wars to value return and from traditional nourishment to consumption upgrades [5][6]. - Dong'e Ejiao holds a dominant market share of 70% in the ejiao block category, indicating a strong competitive position [5]. Policy Support - The national push for high-quality development in traditional Chinese medicine provides a favorable environment for Dong'e Ejiao's expansion into health consumer goods [7]. Challenges Ahead - The construction of the industrial park will take 2-3 years, and the company must ensure that production capacity aligns with rapidly changing market demands [8]. - The health consumer goods sector is highly competitive, requiring innovative product development to meet the needs of younger consumers [8]. - The company needs to enhance its online sales channels and improve operational efficiency to compete effectively in the new retail landscape [8]. Industry Implications - Dong'e Ejiao's strategy serves as a reference for traditional Chinese medicine companies, emphasizing the need for product innovation and industry upgrades to achieve sustainable development [9].

近年来，东阿阿胶（000423）把培育"第二增长曲线"放在公司发展的紧要位置。2月11日，东阿阿胶宣 布，拟以14.85亿元投资建设健康消费品产业园项目，将匹配年轻消费群体对滋补健康产品的消费诉 求。 具体来看，2月11日，东阿阿胶发布公告称，公司拟以14.85亿元（其中固定资产投资14.21亿元，铺底流 动资金0.64亿元）的自有资金投资建设健康消费品产业园项目，用于药食同源食品、保健品、功能性食 品等健康消费品的生产与配套仓储物流、质检中心、新品孵化中心、电商分拣及药品成品仓储等。 据了解，东阿阿胶主要从事阿胶和阿胶系列及其他中成药等产品的研发、生产和销售。 目前，东阿阿胶阿胶及系列产品为公司贡献较大营收。2025年上半年，东阿阿胶来自阿胶及系列产品的 营业收入为28.45亿元，占比超九成。 值得一提的是，近年来，东阿阿胶逐渐面临原材料供应紧张的情况。近年来，国内驴存栏量下降已成为 行业共识，阿胶的主要原料驴皮也随之紧俏。 据了解，近年来，全国各地驴肉价格呈现快速上涨态势，从活驴收购到终端零售均承受一定压力。截至 2026年初，驴肉价格仍处于高位。 东阿阿胶曾在2025年半年报中直言，随着农业运输机械化的 ...